The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden
Abstract Soluble ST2 (sST2) is released in response to vascular congestion, inflammation, and pro-fibrotic stimuli. In heart failure (HF), elevated levels of sST2 are associated with a higher risk of adverse clinical outcomes. Emerging evidence suggests that carbohydrate antigen 125 (CA125) may act...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-01-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-024-84622-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832594781753049088 |
|---|---|
| author | Elena Revuelta-López Rafael de la Espriella Gema Miñana Enrique Santas Sandra Villar Juan Sanchis Antoni Bayés-Genís Julio Núñez |
| author_facet | Elena Revuelta-López Rafael de la Espriella Gema Miñana Enrique Santas Sandra Villar Juan Sanchis Antoni Bayés-Genís Julio Núñez |
| author_sort | Elena Revuelta-López |
| collection | DOAJ |
| description | Abstract Soluble ST2 (sST2) is released in response to vascular congestion, inflammation, and pro-fibrotic stimuli. In heart failure (HF), elevated levels of sST2 are associated with a higher risk of adverse clinical outcomes. Emerging evidence suggests that carbohydrate antigen 125 (CA125) may act as a ligand that modulates the inflammatory response. We hypothesized that CA125 might be modulating sST2 activity. In a cohort of 160 patients with acute (AHF) and renal dysfunction, we investigated whether the prognostic value of sST2 varies according to CA125 levels. The endpoints were: (a) total cardiovascular and renal hospitalizations and (b) all-cause mortality during follow-up. Cox regression analyses assessed the association between admission sST2 and endpoints across CA125 (≤ 35 vs. > 35 U/ml). This sub-study of the IMPROVE-HF trial shows that sST2 predicted the composite of cardiovascular or renal rehospitalizations when CA125 was elevated (> 35 U/ml) but not when CA125 ≤ 35 U/ml. These results highlight a potential biological interaction between sST2 and CA125, suggesting that CA125 status may refine the prognostic utility of sST2 in AHF. Clinically, these insights could guide personalized risk stratification and management strategies in this high-risk population. |
| format | Article |
| id | doaj-art-99ce8672cdbc4bc4a824b4e8463db996 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-99ce8672cdbc4bc4a824b4e8463db9962025-01-19T12:19:32ZengNature PortfolioScientific Reports2045-23222025-01-0115111010.1038/s41598-024-84622-7The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burdenElena Revuelta-López0Rafael de la Espriella1Gema Miñana2Enrique Santas3Sandra Villar4Juan Sanchis5Antoni Bayés-Genís6Julio Núñez7Cardiology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de BarcelonaCIBER CardiovascularCardiology Department, Hospital Clínico Universitario, INCLIVA. Universitat de ValènciaCardiology Department, Hospital Clínico Universitario, INCLIVA. Universitat de ValènciaCardiology Department, Hospital Clínico Universitario, INCLIVA. Universitat de ValènciaCIBER CardiovascularCardiology Department, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de BarcelonaCIBER CardiovascularAbstract Soluble ST2 (sST2) is released in response to vascular congestion, inflammation, and pro-fibrotic stimuli. In heart failure (HF), elevated levels of sST2 are associated with a higher risk of adverse clinical outcomes. Emerging evidence suggests that carbohydrate antigen 125 (CA125) may act as a ligand that modulates the inflammatory response. We hypothesized that CA125 might be modulating sST2 activity. In a cohort of 160 patients with acute (AHF) and renal dysfunction, we investigated whether the prognostic value of sST2 varies according to CA125 levels. The endpoints were: (a) total cardiovascular and renal hospitalizations and (b) all-cause mortality during follow-up. Cox regression analyses assessed the association between admission sST2 and endpoints across CA125 (≤ 35 vs. > 35 U/ml). This sub-study of the IMPROVE-HF trial shows that sST2 predicted the composite of cardiovascular or renal rehospitalizations when CA125 was elevated (> 35 U/ml) but not when CA125 ≤ 35 U/ml. These results highlight a potential biological interaction between sST2 and CA125, suggesting that CA125 status may refine the prognostic utility of sST2 in AHF. Clinically, these insights could guide personalized risk stratification and management strategies in this high-risk population.https://doi.org/10.1038/s41598-024-84622-7CA125Heart failureInflammatory modulatorsST2 |
| spellingShingle | Elena Revuelta-López Rafael de la Espriella Gema Miñana Enrique Santas Sandra Villar Juan Sanchis Antoni Bayés-Genís Julio Núñez The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden Scientific Reports CA125 Heart failure Inflammatory modulator sST2 |
| title | The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden |
| title_full | The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden |
| title_fullStr | The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden |
| title_full_unstemmed | The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden |
| title_short | The modulating effect of circulating carbohydrate antigen 125 on ST2 and long-term recurrent morbidity burden |
| title_sort | modulating effect of circulating carbohydrate antigen 125 on st2 and long term recurrent morbidity burden |
| topic | CA125 Heart failure Inflammatory modulator sST2 |
| url | https://doi.org/10.1038/s41598-024-84622-7 |
| work_keys_str_mv | AT elenarevueltalopez themodulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT rafaeldelaespriella themodulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT gemaminana themodulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT enriquesantas themodulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT sandravillar themodulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT juansanchis themodulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT antonibayesgenis themodulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT julionunez themodulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT elenarevueltalopez modulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT rafaeldelaespriella modulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT gemaminana modulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT enriquesantas modulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT sandravillar modulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT juansanchis modulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT antonibayesgenis modulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden AT julionunez modulatingeffectofcirculatingcarbohydrateantigen125onst2andlongtermrecurrentmorbidityburden |